

## **LISTING OF CLAIMS**

Claims 1-36 (canceled)

37- (currently amended) A compound selected from those of formula (I):

$$N - Alk \qquad Y'$$

$$V = V$$

$$V$$

$$V$$

$$V$$

$$V$$

$$V$$

$$V$$

$$V$$

wherein:

- m and n, which may be identical or different, each represent 1 an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive,
- p and q, which may be identical or different, each represent 1 an integer from 0 to 2 inclusive,
- Alk represents an alkylene, alkenylene or alkynylene chain,
- Y and Y', which may be identical or different, each represent a hydrogen atom, a halogen atom or an alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, mercapto, hydroxy, perhaloalkyl, nitro, amino unsubstituted or substituted by one or two alkyl groups, acyl, aminocarbonyl optionally substituted on the nitrogen atom by one or two alkyl groups, acylamino optionally substituted on the nitrogen atom by an alkyl group, alkoxycarbonyl, carboxy, sulpho or cyano group,
- X represents an oxygen atom, a sulphur atom or an -N(R)- group wherein R represents a hydrogen atom or an alkyl group,
- W represents a group selected from cyano, when X represents an oxygen atom or an NR group,  $-N(R_1)-Z_1-R_2$  and  $-Z_2-NR_1R_2$ ,

## wherein:

- $Z_1$  represents -C(O)-, -C(S)-, -C(NR<sub>4</sub>)-, \*-C(O)-N(R<sub>3</sub>)-, \*-C(S)-N(R<sub>3</sub>)-, \*-C(NR<sub>4</sub>)-N(R<sub>3</sub>)-, \*-C(O)-O-, \*-C(S)-O- or -S(O)<sub>r</sub>-, wherein r represents 1 or 2, and \* corresponds to the attachment to N(R<sub>1</sub>),
- $Z_2$  represents -C(O)-, -C(S)-,  $-C(NR_4)$ -,  $-S(O)_r$  or a bond,
- R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub>, which may be identical or different, each represent a hydrogen atom, an optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted alkynyl group, alkoxy group, optionally substituted cycloalkyl group, optionally substituted heterocycloalkyl group, or optionally substituted heterocycloalkyl group, or optionally substituted heterocycloalkyl group,
- or R<sub>1</sub> and R<sub>2</sub> or R<sub>2</sub> and R<sub>3</sub>, together with the atom or atoms carrying them, form an optionally substituted heterocycloalkyl or optional substituted heterocycloalkyl or opti

its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base,

## it being understood that:

- alkyl means a linear or branched hydrocarbon chain having from 1 to 6 carbon atoms,
- alkenyl means a linear or branched group having from 3 to 6 carbon atoms and from 1 to 3 double bonds,
- alkynyl means a linear or branched group having from 3 to 6 carbon atoms and from 1 to 3 triple bonds,
- alkoxy means an alkyl-oxy group in which the linear or branched alkyl chain has from 1 to 6 carbon atoms,
- optionally substituted aryloxy means a group of which the aryl group is optionally substituted,
- acyl means an R<sub>a</sub>C(O)- group in which R<sub>a</sub> represents a hydrogen atom or an alkyl group,
- perhaloalkyl means a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms,

- alkylene means a linear or branched bivalent radical having from 1 to 6 carbon atoms,
- alkenylene means a linear or branched bivalent radical having from 2 to 6 carbon atoms and from 1 to 3 double bonds,
- alkynylene means a linear or branched bivalent radical having from 2 to 6 carbon atoms and from 1 to 3 triple bonds,
- aryl means a phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl or tetrahydronaphthyl group,
- heteroaryl means a monocyclic or bicyclic group in which at least one of the rings is aromatic, the group having from 5 to 11 ring members and from 1 to 4 hetero atoms selected from nitrogen, oxygen and sulphur,
- cycloalkyl means a hydrocarbon monocycle or bicycle having from 3 to 11 carbon atoms and optionally unsaturated by 1 or 2 unsaturated bonds,
- heterocycloalkyl means a mono- or bi-cyclic group, saturated or unsaturated by 1 or 2 unsaturated bonds, having from 4 to 11 ring members and having from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur,
- optionally substituted as applied to the terms cycloalkyl, and aryl, heteroaryl and heterocycloalkyl means i) the group may be substituted by 1 to 3 identical or different substituents selected from alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, halogen, hydroxy, mercapto, perhaloalkyl, nitro, amino unsubstituted or substituted by one or two alkyl groups, acyl, aminocarbonyl optionally substituted on the nitrogen atom by one or two alkyl groups, acylamino optionally substituted on the nitrogen atom by an alkyl group, alkoxycarbonyl, carboxy, sulpho and cyano; or ii) the group may be substituted by an aryl, heteroaryl, cycloalkyl, heterocycloalkyl or benzyl group; it being understood that the aryl or heteroaryl group may in addition be substituted by one or two oxo groups on the non-aromatic moiety of a group having both non aromatic and aromatic moieties and that the cycloalkyl group or heterocycloalkyl groups may likewise be substituted by one or two oxo groups,
- optionally substituted as applied to the term alkyl, alkenyl or alkynyl means the group may be substituted by one or two identical or different groups selected from

alkylthio, alkylsulphinyl, alkylsulphonyl, alkoxy, halogen, hydroxy, mercapto, nitro,

amino, acyl, aminocarbonyl, acylamino, alkoxycarbonyl, carboxy, sulpho, cyano,

optionally substituted aryl, optionally substituted heteroaryl, optionally substituted

cycloalkyl, optionally substituted heterocycloalkyl and optionally substituted aryloxy.

38- (previously presented) The compound of Claim 37, wherein q is 1, its enantiomers,

diastereoisomers, and addition salts thereof with one or more pharmaceutically

acceptable acid or base.

39- (previously presented) The compound of Claim 37, wherein n is 1, its enantiomers,

diastereoisomers, and addition salts thereof with one or more pharmaceutically

acceptable acid or base.

40- (previously presented) The compound of Claim 37, wherein m is 1, its enantiomers,

diastereoisomers, and addition salts thereof with one or more pharmaceutically

acceptable acid or base.

<u>41</u>- (canceled)

42- (previously presented) The compound of Claim 37, wherein p is 1, its enantiomers,

diastereoisomers, and addition salts thereof with one or more pharmaceutically

acceptable acid or base.

<u>43</u>- (canceled)

44- (previously presented) The compound of Claim 37, wherein X represents an oxygen

atom or a sulphur atom, its enantiomers, diastereoisomers, and addition salts thereof with

one or more pharmaceutically acceptable acid or base.

US Serial No. 10/589,831

Response and Amendment of March 10, 2009

**SERVIER 503 PCT** 

<u>45</u>- (previously presented) The compound of Claim 37, wherein X represents an -N(R)-group, its enantiomers, diastereoisomers, and addition salts thereof with one or more

group, its characteristic and addition can all the control of the characteristic and addition can be also as a control of the characteristic and addition can be also as a control of the characteristic and addition can be also as a control of the characteristic and a control of the

pharmaceutically acceptable acid or base.

46- (previously presented) The compound of Claim 37, wherein Y and Y' represent a

hydrogen atom, its enantiomers, diastereoisomers, and addition salts thereof with one or

more pharmaceutically acceptable acid or base.

47- (previously presented) The compound of Claim 37, wherein Y represents a hydrogen

atom and Y' represents a halogen atom or an alkyl, alkoxy, alkylthio, alkylsulphinyl,

alkylsulphonyl, mercapto, hydroxy, perhaloalkyl, nitro, amino unsubstituted or

substituted by one or two alkyl groups, acyl, aminocarbonyl optionally substituted on the

nitrogen atom by one or two alkyl groups, acylamino optionally substituted on the

nitrogen atom by an alkyl group, alkoxycarbonyl, carboxy, sulpho or cyano group, its

enantiomers, diastereoisomers, and addition salts thereof with one or more

pharmaceutically acceptable acid or base.

48- (previously presented) The compound of Claim 37, wherein Alk represents an

alkylene chain, its enantiomers, diastereoisomers, and addition salts thereof with one or

more pharmaceutically acceptable acid or base.

49- (previously presented) The compound of Claim 37, wherein W is located on the

phenyl group in the 4-position, its enantiomers, diastereoisomers, and addition salts

thereof with one or more pharmaceutically acceptable acid or base.

<u>50</u>- (previously presented) The compound of Claim 37, wherein W represents a cyano

group, its enantiomers, diastereoisomers, and addition salts thereof with one or more

pharmaceutically acceptable acid or base.

US Serial No. 10/589,831 Response and Amendment of March 10, 2009

**SERVIER 503 PCT** 

<u>51</u>- (previously presented) The compound of Claim 37, wherein W represents an  $-N(R_1)$ – $Z_1$ – $R_2$  group, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>52</u>- (previously presented) The compound of Claim 37, wherein W represents a  $-Z_2$ -NR<sub>1</sub>R<sub>2</sub> group, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>53</u>- (previously presented) The compound of Claim 37, wherein  $Z_2$  represents a group selected from -C(O)-, -C(S)-,  $-C(NR_4)$ - and  $-S(O)_r$ -, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>54</u>- (previously presented) The compound of Claim 37, wherein  $Z_2$  represents a bond, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>55</u>- (previously presented) The compound of Claim 37, wherein  $Z_1$  represents a group selected from -C(O)-, -C(S)-, \*-C(O)- $N(R_3)$ -, \*-C(S)- $N(R_3)$ -, \*-C(O)-O- and  $-S(O)_2$ -, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>56</u>- (currently amended) The compound of Claim 37, wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$ , which may be identical or different, each represent a hydrogen atom or a group selected from cycloalkyl; alkoxy; optionally substituted phenyl; naphthyl; a heteroaryl group; and an alkyl group optionally substituted by

- an optionally substituted phenyl group,
- a cycloalkyl group,
- a heterocycloalkyl group,
- a heteroaryl group,
- one or two alkoxy groups, or

- a phenyloxy group

its enantiomers, diastereoisomers, and addition salts thereof with one or more

pharmaceutically acceptable acid or base.

<u>57</u>- (canceled)

 $\underline{\textbf{58}}$ - (currently amended) The compound of Claim 37, wherein W represents a  $-Z_2$ -NR<sub>1</sub>R<sub>2</sub>

group in which Z<sub>2</sub> represents a bond;

R<sub>1</sub> and R<sub>2</sub>, together with the nitrogen atom carrying them, form a heteroaryl group or R<sub>1</sub>

represents a hydrogen atom or an alkyl group and R2 represents an aryl or heteroaryl

group, its enantiomers, diastereoisomers, and addition salts thereof with one or more

pharmaceutically acceptable acid or base.

59- (currently amended) The compound of Claim 37, wherein W represents a -C(O)-

NR<sub>1</sub>R<sub>2</sub> group in which R<sub>1</sub> and R<sub>2</sub>, independently, each represent an alkyl group or a

hydrogen atom, or-R<sub>1</sub>-and-R<sub>2</sub>, together with the nitrogen atom carrying them, form a

group selected from piperazinyl optionally substituted by an alkyl or benzyl group;

piperidyl optionally substituted by an alkyl or benzyl group; morpholinyl; azepanyl;

thiomorpholinyl; octahydrocyclopentapyrrolyl; dihydroquinolinyl and

tetrahydroquinolinyl, its enantiomers, diastereoisomers, and addition salts thereof with

one or more pharmaceutically acceptable acid or base.

60- (previously presented) The compound of Claim 37, wherein W represents a

-C(O)-NR<sub>1</sub>R<sub>2</sub> group in which R<sub>1</sub> and R<sub>2</sub>, independently, each represent an alkyl group or

a hydrogen atom, its enantiomers, diastereoisomers, and addition salts thereof with one or

more pharmaceutically acceptable acid or base.

<u>61</u>- (previously presented) The compound of Claim 37, wherein W represents a  $-N(R_1)$ -

C(O)-R<sub>2</sub> group in which R<sub>1</sub> and R<sub>2</sub>, independently, each represent an alkyl group or a

hydrogen atom, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base.

<u>62</u>- (previously presented) The compound of Claim 37, which is 4-(3-hexahydrocyclopenta [c] pyrrol-2(1H)-ylpropoxy) benzonitrile, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid.

<u>63</u>- (previously presented) The compound of Claim 37, which is 4-(3-hexahydrocyclopenta[c]-pyrrol-2(1H)-ylpropoxy)benzamide, its enantiomers, diastereo-isomers, and addition salts thereof with one or more pharmaceutically acceptable acid.

<u>64</u>- (previously presented) The compound of Claim 37, which is 4-[3-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)propoxy]-N-methyl-benzamide, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid.

<u>65</u>- (previously presented) The compound of Claim 37, which is 4-[3-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)propoxy]-N,N-dimethyl-benzamide, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid.

<u>66</u>- (previously presented) The compound of Claim 37, which is N-[4-(3-hexahydrocyclopenta[c]pyrrol-2(1H)-ylpropoxy)phenyl]acetamide its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid.

<u>67</u>- (previously presented) A pharmaceutical composition comprising as active ingredient a compound of Claim 37, alone or in combination with one or more pharmaceutically acceptable, inert, non-toxic excipients or carriers.

68- (currently amended) A method for treating a living animal body, including a human, afflicted with a condition selected from eognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases, and also in the treatment of mood disorders, convulsive attacks, attention deficit hyperactivity syndrome, obesity, and pain, and cognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases comprising the step of administering to the living animal body, including a human, an amount of the compound of Claim 37 which is effective for alleviation of the condition.

69- (currently amended) A method for treating a living animal body, including a human, afflicted with a condition selected from cognitive deficiencies associated with Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal and sub-cortical dementias of vascular or other origins comprising the step of administering to the living animal body, including a human, an amount of the compound of Claim 37 which is effective for alleviation of the condition.

[[.]]